Clinical Trial Update: Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis [Phase 2]

View source ↗

Summary

Phase 2 trial update involving pyrotinib, trastuzumab, and Abraxane for HER2-positive metastatic breast cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN